FDA hits Kezar's zetomipzomib program with 2nd clinical hold in 2 months

Kezar Life Sciences has been hit by its second clinical hold from the FDA in as many months.

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor zetomipzomib in 24 patients with autoimmune hepatitis.